PH12017550051A1 - A pharmaceutical composition for treating gastrointestinal diseases - Google Patents

A pharmaceutical composition for treating gastrointestinal diseases

Info

Publication number
PH12017550051A1
PH12017550051A1 PH12017550051A PH12017550051A PH12017550051A1 PH 12017550051 A1 PH12017550051 A1 PH 12017550051A1 PH 12017550051 A PH12017550051 A PH 12017550051A PH 12017550051 A PH12017550051 A PH 12017550051A PH 12017550051 A1 PH12017550051 A1 PH 12017550051A1
Authority
PH
Philippines
Prior art keywords
pharmaceutical composition
gastrointestinal diseases
treating gastrointestinal
sucralfate
ranitidine
Prior art date
Application number
PH12017550051A
Inventor
Young Ho Jo
Jun Woo Lee
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12017550051(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of PH12017550051A1 publication Critical patent/PH12017550051A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a pharmaceutical composition for treating gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients and a preparation method thereof. According to the present invention, when a combination drug of ranitidine, sucralfate and bismuth subcitrate is prepared, it is possible to address a hygroscopicity problem of ranitidine and increase formulation stability and drug bioavailability by controlling particle sizes of sucralfate and bismuth subcitrate.
PH12017550051A 2015-01-30 2017-07-25 A pharmaceutical composition for treating gastrointestinal diseases PH12017550051A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (en) 2015-01-30 2015-10-22 A pharmaceutical composition for treating gastrointestinal diseases
PCT/KR2016/000935 WO2016122226A2 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases

Publications (1)

Publication Number Publication Date
PH12017550051A1 true PH12017550051A1 (en) 2018-01-29

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017550051A PH12017550051A1 (en) 2015-01-30 2017-07-25 A pharmaceutical composition for treating gastrointestinal diseases

Country Status (19)

Country Link
EP (1) EP3250199A4 (en)
JP (1) JP6419347B2 (en)
KR (2) KR101583452B1 (en)
CN (1) CN107205947B (en)
AR (1) AR105413A1 (en)
CL (1) CL2017001680A1 (en)
CO (1) CO2017006222A2 (en)
EA (1) EA032385B9 (en)
EC (1) ECSP17038599A (en)
GE (1) GEP20196941B (en)
MA (1) MA41432A (en)
MX (1) MX2017007567A (en)
MY (1) MY195824A (en)
PE (1) PE20171340A1 (en)
PH (1) PH12017550051A1 (en)
SA (1) SA517382016B1 (en)
TW (1) TWI635859B (en)
UA (1) UA116517C2 (en)
WO (1) WO2016122226A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (en) 2017-10-11 2019-09-24 (주)휴럼 Litsenolide used as an active ingredient for gastrointestinal disease, and A composition comprising the same as an active ingredient
JP2021518422A (en) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ Pharmaceutical composition containing lenalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81011T1 (en) * 1987-03-09 1992-10-15 Procter & Gamble COMPOSITIONS AND THEIR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (en) * 1992-01-22 1997-04-23 주식회사 대웅제약 A pharmaceutical composition for treating gastrointestinal disorders
BR9507533A (en) * 1994-04-26 1997-09-02 Chugai Pharmaceutical Co Ltd Fused granulated sucralfate preparations and a process for their production
JPH0879097A (en) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd Portable radio equipment
KR970006083A (en) 1995-07-06 1997-02-19 한승준 Installation structure of wire fixing device of automobile cowl
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
AU4655199A (en) 1999-06-21 2001-01-09 Dae Woong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (en) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk Compounding agent for treating/preventing gastritis
WO2010001930A1 (en) * 2008-07-01 2010-01-07 ライオン株式会社 Solid preparation for internal application
KR20110105223A (en) * 2010-03-18 2011-09-26 일양약품주식회사 Oral pharmaceutical composition for preventing or treating a gastroenteric disease comprising ilaprazole and a mixture of sucralfate and bismuth agents
KR20140072673A (en) 2012-12-05 2014-06-13 (주)한국파비스제약 Oral tablet for treatment of gastrointestinal disease

Also Published As

Publication number Publication date
UA116517C2 (en) 2018-03-26
WO2016122226A3 (en) 2016-09-15
PE20171340A1 (en) 2017-09-13
CN107205947A (en) 2017-09-26
MY195824A (en) 2023-02-22
CN107205947B (en) 2020-05-22
EA032385B9 (en) 2019-07-31
BR112017013857A2 (en) 2018-02-27
EP3250199A2 (en) 2017-12-06
ECSP17038599A (en) 2017-09-29
CL2017001680A1 (en) 2018-01-12
EP3250199A4 (en) 2018-08-08
TWI635859B (en) 2018-09-21
KR101583452B1 (en) 2016-01-11
EA032385B1 (en) 2019-05-31
CO2017006222A2 (en) 2017-09-20
AR105413A1 (en) 2017-10-04
GEP20196941B (en) 2019-01-10
KR20160094268A (en) 2016-08-09
SA517382016B1 (en) 2021-03-18
KR101583452B9 (en) 2022-05-02
TW201639559A (en) 2016-11-16
WO2016122226A2 (en) 2016-08-04
MX2017007567A (en) 2017-10-19
JP2018503672A (en) 2018-02-08
JP6419347B2 (en) 2018-11-07
EA201791458A1 (en) 2017-11-30
MA41432A (en) 2017-12-05

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
SG11202106160WA (en) Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient
WO2014147611A8 (en) Quinolines derivatives as novel anticancer agents
CN108026053A8 (en) Condensed glyoxaline compound as mIDH1 inhibitor
EP3312175A4 (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
PH12020550341A1 (en) Niraparib formulations
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
HK1257615A1 (en) Pharmaceutical composition for treatment of cancer, containing polyphenol compound as active ingredient
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EP3539951A4 (en) Novel pyrimidine compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer and inflammatory diseases
EP3604304A4 (en) Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
EP3279210A4 (en) Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
EP3336100A4 (en) Peptide having effect of preventing or treating central nervous system diseases and pharmaceutical composition for preventing and treating central nervous system diseases, containing same as active ingredient
PH12017550051A1 (en) A pharmaceutical composition for treating gastrointestinal diseases
EP3311817A4 (en) Pharmaceutical composition for preventing and treating dry eye diseases, containing imatinib as active ingredient
WO2015001541A3 (en) Pharmaceutical film composition
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
EP3603656A4 (en) Pharmaceutical composition for prevention or treatment of gynecological diseases containing extract of sarcodon imbricatus as active ingredient
EP3610866A4 (en) Pharmaceutical composition for preventing and treating cancer, containing malate-aspartate shuttle inhibitor and anticancer drug as active ingredients
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds